{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-347869","form_type":"8-K","ticker":"PBLS","cik":"0001657677","company_name":"Parabilis Medicines, Inc.","filed_at":"2026-08-13T11:19:04+00:00","discovered_at":"2026-08-13T11:20:00.294101+00:00","generated_at":"2026-08-13T11:20:15.993705+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Parabilis Q2 net loss $52.5M; $1.1B cash after $770.5M IPO; Regeneron deal up to $2.2B","bullets":["Net loss $52.5M in Q2 2026 vs $34.8M prior year; R&D $39.4M, G&A $11.7M.","Cash $1.1B as of June 30, 2026 (vs $27.7M Dec 31, 2025) after $770.5M IPO at $20.00/share; funds ops into 2030.","Regeneron collaboration: $125M received ($50M upfront + $75M equity); up to $2.2B milestones plus low double-digit tiered royalties for Antibody-Helicon Conjugates.","Zolucatetide: ESMO 2026 abstract accepted; FDA alignment Q4 2026; Phase 3 desmoid trial initiation H1 2027; FAP cohort H2 2026.","Leadership: Helen Ho (Chief Business & Strategy Officer), Tom Kotarakos (CFO), Alan M. Sebulsky to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-347869","json":"https://secwatch.observer/filing/0001193125-26-347869.json","markdown":"https://secwatch.observer/filing/0001193125-26-347869.md","text":"https://secwatch.observer/filing/0001193125-26-347869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526347869/0001193125-26-347869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526347869/ck0001657677-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T11:20:15.993705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}